OBJECTIVE: To study clinical outcomes of recombinant @entity1456 (alteplase) as primary fibrinolytic drug in @entity1 with acute STEMI in Buriram Hospital. MATERIAL AND METHOD: Data on demographics, medications, in-hospital outcomes, and angiography were collected from a prospective registry of STEMI @entity1 admitted by STEMI fast track from January 1, 2011 to December 31, 2013. RESULTS: During the 3-year period, 97 consecutive @entity1 with STEMI who received alteplase were enrolled. The mean age was 64.3 year and 75.3% were male. There were high prevalence of @entity2299 and current smoking. Median time from symptom onset to hospital presentation was 170 minutes. Median door to needle time was 30 minutes. Thrombolytic therapy was started in 30 minutes in 55. 7% of cases. Overall @entity548 was 19.6%. @entity932 was 1.0% of @entity1 . ST-segment resolution was found in 79.4% of @entity1 . In-hospital mortality was 11.3%. Angiographic data (n = 45) in @entity1 with clinical reperfusion (n = 32), TIMI flow grade 2 and 3 combined was 90.6% and TIMI flow grade 3 was 56.3%. Revascularization was performed in 90.6%. CONCLUSION: Alteplase in acute STEMI provided good clinical reperfusion with minimal major @entity548 complication. Most of @entity1 with clinical reperfusion required additional percutaneous coronary intervention to fix residual stenosis of @entity1188 related artery.

Outcome of recombinant XXXX in ST-segment elevation myocardial infarction in Buriram Hospital.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity932 :: ('MESH:D020300', 'Disease') :: ['Intracranial hemorrhage'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia'] @entity1456 :: ('100128998', 'Gene') :: ['tissue plasminogen activator'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct']
@entity1456 :: (100128998,Gene) :: ['tissue plasminogen activator']
